Drug intelligence / Profile preview

Amelparib

Development stage: Phase 2
Lead developer: Jeil Pharmaceutical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Amelparib (JPI-289) is a potent, orally active and water-soluble small molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP-1). It acts by inhibiting PARP-1 activity in the nanomolar range and has demonstrated neuroprotective effects in preclinical models by reducing infarct volume and apoptosis following ischemic stroke. Amelparib is under development primarily for acute ischemic stroke and myocardial infarction. The drug is being developed by Jeil Pharmaceutical and has reached Phase 2 clinical trials for both acute ischemic stroke and myocardial infarction. Its mechanism of action involves inhibition of necrosis, apoptosis, and inflammation through PARP-1 blockade[1][3][4][5][6][7].

Other names: amelparib

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on Amelparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amelparib.

Explore the full profile